Name the change you actually want

Hair shedding, a receding hairline, dry skin, wrinkles, and slow wound healing are different concerns. Grouping them together as rejuvenation obscures the fact that each requires its own evaluation and evidence.

A useful discussion starts with the specific change: when it appeared, whether it is progressing, and whether there are associated symptoms. A cosmetic concern can still deserve medical attention without assuming that growth hormone signaling is the cause.

When a provider presents one peptide as a solution for all of these issues, ask which clinical studies measured each promised outcome. A mechanism described in a diagram cannot substitute for those studies.

The familiar older-men study used growth hormone

Rudman and colleagues’ 1990 report examined human growth hormone in older men and included skin thickness among its measurements. It did not test sermorelin, and skin thickness is not the same outcome as reduced wrinkles, improved appearance, or regrown scalp hair.

The result can contribute to understanding how hormone exposure affects tissue. It cannot establish the cosmetic effectiveness of another drug or formulation. A lozenge, injection, and topical product also need to be distinguished.

When you see the study cited under a sermorelin before-and-after photograph, ask whether the image documents a controlled study or simply accompanies an unrelated reference. The presence of a real paper does not guarantee that the adjacent claim is supported.

There is a further statistical detail worth keeping: the reported change in skin thickness in the 1990 paper did not reach conventional statistical significance, and the between-group difference also was not significant. A positive-looking percentage can therefore give a stronger impression than the analysis supports. Reporting the direction of a result without its uncertainty is especially misleading when it is then attached to a different medication.

Collagen measurements need clinical context

A change in a laboratory marker or tissue measurement may be scientifically interesting. To establish a useful skin benefit, researchers still need to show how that change affects the concern being treated.

For example, a cosmetic claim might need standardized photographs, a defined assessment method, appropriate comparison groups, and enough follow-up to judge persistence and unwanted effects. “Supports collagen” leaves all of those questions open.

It also matters whether the study tested an isolated ingredient, a blend, or a completely different intervention. A collection of papers about growth factors does not become a body of evidence for one compounded sermorelin preparation.

Hair-growth promises need hair-growth studies

In the targeted search for this article, we did not identify a clinical trial establishing sermorelin as an effective treatment for scalp hair loss. That is a finding about the evidence located, not a statement that every possible unpublished experiment has been excluded.

If a provider has relevant data, ask for the study and check that it actually tested sermorelin. Similar-sounding substances and studies of cells or isolated follicles can easily be mistaken for trials in people.

Useful clinical evidence would specify the type of hair loss, objective changes in hair density or another appropriate outcome, the comparator, and adverse effects. Testimonials cannot resolve these questions because other treatments, natural fluctuation, and photographic conditions may explain part of the apparent result.

A more useful consultation

Bring a timeline of the concern and a list of skin, hair, hormone, and supplement products you already use. Ask whether the clinician recommends evaluation by a dermatologist or another specialist before adding a systemic medication.

If sermorelin is still proposed, ask what result would count as success and what evidence supports expecting it. Clarify how the clinician will distinguish treatment effects from changes caused by other products introduced at the same time.

Compounding quality and cosmetic efficacy remain separate questions. A pharmacy’s credentials do not demonstrate hair regrowth or wrinkle reduction. Our pharmacy-verification guide addresses the dispensing side, while the anti-aging evidence article explains why a broader rejuvenation promise needs more than a hormone response.

Sources & further reading

Sources reviewed October 2026. Provider prices and terms may change.

  1. Rudman et al. (1990): growth hormone in older men, not sermorelin
  2. FDA: compounded drugs questions and answers
  3. Vitiello et al. (2006): randomized sermorelin cognition trial, full paper